# A Phase 1/2 Clinical Trial of an Alphavirus Replicon Vaccine for Influenza

> **NCT00440362** · PHASE1,PHASE2 · COMPLETED · sponsor: **AlphaVax, Inc.** · enrollment: 216 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** AVX502
- **BIOLOGICAL:** AVX502
- **BIOLOGICAL:** AVX502
- **BIOLOGICAL:** AVX502
- **BIOLOGICAL:** AVX502
- **BIOLOGICAL:** AVX502
- **BIOLOGICAL:** AVX502
- **BIOLOGICAL:** AVX502
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** Placebo
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00440362
- **Lead sponsor:** AlphaVax, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-04
- **Primary completion:** 2007-09
- **Final completion:** 2007-09
- **Target enrollment:** 216 (ACTUAL)
- **Last updated:** 2008-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00440362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00440362, "A Phase 1/2 Clinical Trial of an Alphavirus Replicon Vaccine for Influenza". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00440362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*